GCP
AUTL

GSA Capital Partners’s Autolus Therapeutics AUTL Stock Holding History

GSA Capital Partners’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-119,546
Closed -$238K – 1704
2025
Q4 		$238K Buy
+119,546
New +$184K 0.02% 1299
2024
Q4 		– Sell
-298,086
Closed -$1.08M – 1596
2024
Q3 		$1.08M Buy
+298,086
New +$1.19M 0.08% 420
2022
Q4 		– Sell
-22,885
Closed -$49K – 1456
2022
Q3 		$49K Buy
+22,885
New +$67.8K 0.01% 1424
2022
Q2 		– Sell
-11,869
Closed -$49K – 1392
2022
Q1 		$49K Sell
11,869
-19,340
-62% -$81.3K 0.01% 1337
2021
Q4 		$162K Sell
31,209
-12,426
-28% -$74.6K 0.02% 1257
2021
Q3 		$286K Buy
+43,635
New +$276K 0.03% 1053
2018
Q3 		– Sell
-35,851
Closed -$960K – 1618
2018
Q2 		$960K Buy
+35,851
New +$947K 0.05% 773

Other funds holding AUTL

MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

GSA Capital Partners's AUTL Position: Q1 2026 in Review

GSA Capital Partners sold out of Autolus Therapeutics (AUTL) in Q1 2026, closing a stake of 119,546 shares — an estimated $238K sold.

GSA Capital Partners first reported a position in AUTL in Q2 2018 and held it in 7 quarters. The position peaked at $1.08M in Q3 2024. 84 funds tracked by Wall St. Rank hold AUTL as of Q1 2026.

  • GSA Capital Partners reported no remaining Autolus Therapeutics position as of Q1 2026 after selling out during the quarter.
  • GSA Capital Partners sold 119,546 Autolus Therapeutics shares in Q1 2026, an estimated $238K.
  • GSA Capital Partners first reported a position in Autolus Therapeutics in Q2 2018 and held it in 7 quarters.
  • GSA Capital Partners's Autolus Therapeutics position peaked at $1.08M in Q3 2024.
  • 84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.